Satellos Bioscience (MSLE) Loans - Gross (2025 - 2026)
Satellos Bioscience (MSLE) posted quarterly Loans - Gross of $8000.0 for Q1 2026, up 60.0% quarter-over-quarter from $5000.0 in Q4 2025.
Satellos Bioscience (MSLE) Loans - Gross (2025 - 2026) Analysis & Trends
Satellos Bioscience (MSLE) has reported Loans - Gross for 2 consecutive years, with $8000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Loans - Gross changed N/A year-over-year to $8000.0; the TTM figure through Mar 2026 stood at $8000.0 (changed N/A YoY), while the FY2025 annual figure was $5000.0, changed N/A from the prior year.
- Loans - Gross grew to $8000.0 in Q1 2026 per MSLE's latest filing, from $5000.0 in the prior quarter.
- Across five years, Loans - Gross topped out at $8000.0 in Q1 2026 and bottomed at $5000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Loans - Gross (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.57 Bn | 131.72 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.71 Bn | 78.72 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 65.44 Bn | 60.25 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.06 Bn | 54.93 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.89 Bn | 28.58 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.11 Bn | 9.72 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.59 Bn | 26.43 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | - |
| 10 | Satellos Bioscience | 207.06 Mn | 207.06 Mn | - | 7,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8,000.00 |
| Dec 31, 2025 | 5,000.00 |